US 12,084,424 B2
Compounds and compositions for treating conditions associated with NLRP activity
Luigi Franchi, Ann Arbor, MI (US); Shomir Ghosh, Brookline, MA (US); Gary Glick, Ann Arbor, MI (US); Jason Katz, Newton, MA (US); Anthony William Opipari, Jr., Dexter, MI (US); William Roush, Boston, MA (US); Hans Martin Seidel, Concord, MA (US); Dong-Ming Shen, Edison, NJ (US); Shankar Venkatraman, Lansdale, PA (US); and David Guenther Winkler, Arlington, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on May 18, 2023, as Appl. No. 18/319,630.
Application 18/319,630 is a continuation of application No. 17/496,375, filed on Oct. 7, 2021, granted, now 11,724,992.
Application 17/496,375 is a continuation of application No. 16/632,849, granted, now 11,203,579, previously published as PCT/US2018/043338, filed on Jul. 23, 2018.
Claims priority of provisional application 62/573,894, filed on Oct. 18, 2017.
Claims priority of provisional application 62/536,271, filed on Jul. 24, 2017.
Prior Publication US 2023/0416211 A1, Dec. 28, 2023
Int. Cl. C07D 277/36 (2006.01); C07C 307/06 (2006.01); C07D 215/36 (2006.01); C07D 231/18 (2006.01); C07D 239/26 (2006.01); C07D 263/46 (2006.01); C07D 307/64 (2006.01); C07D 307/79 (2006.01); C07D 317/62 (2006.01); C07D 333/34 (2006.01); C07D 487/04 (2006.01); C07C 335/42 (2006.01); C07D 213/71 (2006.01); C07D 231/12 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01)
CPC C07D 277/36 (2013.01) [C07C 307/06 (2013.01); C07D 215/36 (2013.01); C07D 231/18 (2013.01); C07D 239/26 (2013.01); C07D 263/46 (2013.01); C07D 307/64 (2013.01); C07D 307/79 (2013.01); C07D 317/62 (2013.01); C07D 333/34 (2013.01); C07D 487/04 (2013.01); C07C 335/42 (2013.01); C07D 213/71 (2013.01); C07D 231/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01)] 3 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein TBS is tert-butyldimethylsilyl and Boc is tert-butyloxy carbonyl, and pharmaceutically acceptable salts thereof.